Sling Therapeutics is a clinical-stage biopharmaceutical company focused on the late-stage advancement of an oral small molecule therapy for the treatment of thyroid eye disease (TED). Linsitinib, an IGF-1R (insulin-like growth factor 1 receptor) inhibitor, is designed to provide TED patients with an effective, convenient oral treatment option while reducing the treatment burden on patients, physicians and the healthcare system.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
09/24/26	$123,000,000	Series C	Forbion Capital Partners Sectoral Asset Management TPG	undisclosed